COVID-19 Vaccine Access Uproar Underscores Importance Of At-Risk Manufacturing

Sanofi CEO Hudson tries to reassure France on access, but notes that Europe does not currently have a program to assure a supply of a coronavirus vaccine as soon as safety and efficacy have been established.

Pile of Money on Fire
Trying to assure the biggest supply of vaccine as soon as possible may mean burning money by making large amounts of the product even before it's been proven to work.

Sanofi CEO Paul Hudson’s suggestion that the US may get priority access to COVID-19 vaccines being developed by the Paris-headquartered company prompted a fury that highlights not just the tense geopolitics of the coronavirus era, but also the logistical hurdles that any successful development program will have to overcome in addition to the scientific challenges.

To wit, if you want a vaccine as fast as possible, you need to be willing to potentially waste a...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet